[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Therapy Trends: Alzheimer's Disease - Breaking New Ground in Disease Modification

April 2012 | 160 pages | ID: T12177CA27BEN

US$ 7,495.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
An incisive, dynamic analytical report that uses insight from the most influential key opinion leaders (KOLs) in Alzheimer’s disease (AD) to map the current treatment landscape and identify future trends.

Alzheimer’s Disease: Breaking new ground in disease modification

By the end of 2012, the Alzheimer’s disease market will reach a pivotal stage with the expected release of Phase III results of disease-modifying therapies, and new research into biomarkers to aid early AD diagnosis. If positive, these results will represent a ground-breaking milestone in AD treatment. Recent trends in the AD market also represent a clear shift in researchers’ approaches to detecting, treating and preventing AD.

‘Therapy Trends: Alzheimer’s Disease’ is compiled from exclusive, in-depth interviews with the world’s leading KOLs in AD. It identifies and analyses the major factors, advances and trends currently influencing the AD treatment landscape. The report focuses on late-stage pipeline products, and how these could modify future AD management


Drive your strategic decision-making with inside intelligence

‘Therapy Trends: Alzheimer’s Disease’ disseminates the critical opinions of KOLs, giving you greater insight to the latest AD market advances. This information includes:
  • The most relevant factors driving the global AD market, allowing you to start planning your business strategies without delay
  • First-hand feedback from the most influential AD KOLs, giving you the strategic head-start you need for informed market decision-making
  • KOL consensus on the future AD treatment algorithm helping you identify the clinical evidence and potential use of new AD therapies
  • KOL opinions on unmet needs and industry challenges allowing you to recognised and capitalise on possible commercial AD opportunities
  • On-going AD report updates for 12 months providing you with fast KOL feedback on the significance of industry events within days of their occurrence.

Critical questions answered

FirstWord selected the KOLs for this Therapy Trends report based on their level of engagement and influence within the AD pharmaceutical industry, and their scientific standing. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how AD clinical research will shape the future market.

These KOLs provided answers to some critical questions regarding the global AD market:
  • What are the current unmet needs and major challenges in AD treatment?
  • What is the most promising late-stage pipeline therapy in disease-modifying development?
  • Which existing first-line therapies for AD face generic erosion in the near future?
  • Where could Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab be positioned in the AD market?
  • How could solanezumab’s different mechanism of action affect its use in AD?
  • In what ways could brain imaging and biomarkers improve future AD disease management?
  • How promising do KOLs think Baxter’s Gammagrad could be as a disease-modifying AD drug?
  • When should potential disease-modifying drugs be started in AD patients?
  • How do KOLs think pricing and safety will shape the uptake of new AD treatments?
  • What clinical research trends do KOLs predict for future AD therapies?
The deliverables

FirstWord’s ‘Therapy Trends: Alzheimer’s Disease’ is delivered to you in two complementary formats:

Therapy Trends Intelligence Report: a concise, in-depth market intelligence research report that examines current and late-stage pipeline products. It identifies future trends in the clinical treatment and diagnosis of AD, and assesses the commercial impact on the AD market landscape.

Therapy Trends Impact Assessments: dynamic analyst briefings that evaluate the impact of events in the AD pharmaceutical market over the next 12 months. These updates will be delivered to you within days of a significant event happening.

Key Benefits
  • Understand the current trends driving and shaping global drug markets
  • Analyse the commercial and clinical potential of major pipeline therapies
  • Develop your strategies and resources based on KOL insight
  • Identify the unmet needs and opportunities for disease management
  • Evaluate the performance of companies with the most robust new product pipelines
  • Recognise the key factors KOLs predict will drive future treatment trends.
For users with responsibilities in:
  • Business Development
  • New Product Planning
  • Market Research
  • Strategic brand planning
  • Forecasting and marketing professionals
  • Medical Affairs
  • Clinical Trials
  • Relationship Management
Informed Intelligence:
  • Exclusive feedback from KOL panels involving leading global experts in the treatment and diagnosis of major medical conditions
  • Consensus ratings of therapeutic developments and events compiled from a collaborative online resource of more than 535,000 vetted physicians
  • Live dispatches and critical industry information from a network of correspondents who attend over 125 medical conferences each year
  • Over 2,000 peer-reviewed medical journals
  • Over 450 pharmaceutical news sources.





Current treatment landscape
Reimbursement of key Alzheimer’s disease brands
Current therapies
Aricept (donepezil; Eiasi/Pfizer) trends
Exelon (rivastigmine; Novartis) trends
Razadyne (galantamine; Johnson & Johnson/Shire) trends
Namenda/Ebixa (memantine; Forest/Merz/Lundbeck) trends
Current treatment algorithm
Unmet needs in Alzheimer’s disease
Late-stage disease-modifying therapies primarily target beta-amyloid
Bapineuzumab (Johnson & Johnson/Pfizer) trends
Solanezumab (LY2062430, Eli Lilly) trends
Gammagard (immune globulin IV [human], Baxter) trends
Future prescribing trends


Clear definition of disease-modifying is required
Improved understanding of underlying disease etiology
Targets beyond beta-amyloid
Gene therapy as a treatment option
Enrolment of trials will be more important for success
Identification of patients earlier in disease course for intervention
Development of biomarkers will aid diagnosis and treatment


Positive Alzheimer’s disease key news events
Negative Alzheimer’s disease key news events


KOL biographies


Alzheimer’s disease news article links

More Publications